Related Experiment Video
Updated: May 28, 2026
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
1Nanomedicine Research Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. aalshamsan@ksu.edu.sa
Abstract:
One scenario by which tumors escape immune recognition is the constitutive activation of signal transducer and activator of transcription 3 (STAT3). This transcription factor mediates the production of tumor-derived factors that negatively influence target immune cells, such as dendritic cells, and polarize them toward immune-tolerance also through the induction of STAT3 activation. In the current study, the effect of p-STAT3-positive murine colon carcinoma cell line (CT26) on bone marrow-derived DCs was examined. The results showed a remarkable increase in p-STAT3 in dendritic cells (DCs) only after CT26-CM incubation. The induction of p-STAT3 in CT26-CM exposed DCs was attributed at least in part to the high levels of interleukin-6 secreted by CT26 in culture. This was also accompanied by a significant reduction in the response to the immunostimulatory adjuvant lipopolysaccharide by lowering the expression of co-stimulatory molecules CD86 and CD40. Taken together, the results suggest an inhibitory effect of CT26 colon carcinoma on DC maturation through induction of STAT3 phosphorylation. Therefore, tumor-induced p-STAT3 in DCs can be seen as a promising target for colon cancer immunotherapy.
Insights
Tumors evade immune detection via activated signal transducer and activator of transcription 3 (STAT3). This study shows colon cancer cells inhibit dendritic cell maturation by inducing STAT3 phosphorylation, a potential immunotherapy target.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor cells can evade immune detection through constitutive activation of signal transducer and activator of transcription 3 (STAT3).
- STAT3 activation mediates the production of tumor-derived factors that suppress immune cells like dendritic cells (DCs), promoting immune tolerance.
- STAT3 signaling plays a critical role in immune regulation and cancer progression.
Purpose of the Study:
- To investigate the effect of a p-STAT3-positive murine colon carcinoma cell line (CT26) on bone marrow-derived dendritic cells (DCs).
- To elucidate the mechanism by which colon cancer cells influence DC function and maturation.
- To identify STAT3 phosphorylation in DCs as a potential therapeutic target for colon cancer immunotherapy.
Main Methods:
- Co-incubation of bone marrow-derived DCs with conditioned medium (CM) from CT26 colon carcinoma cells.
- Assessment of phosphorylated STAT3 (p-STAT3) levels in DCs using Western blotting or similar techniques.
- Evaluation of DC response to lipopolysaccharide (LPS) stimulation, including the expression of co-stimulatory molecules (CD86, CD40).
Main Results:
- CT26-CM incubation significantly increased p-STAT3 levels in DCs.
- The induction of p-STAT3 in DCs was associated with high levels of interleukin-6 (IL-6) secreted by CT26 cells.
- DCs exposed to CT26-CM showed reduced expression of CD86 and CD40, indicating impaired maturation and response to immunostimulatory signals.
- A significant reduction in the response to lipopolysaccharide (LPS) was observed in treated DCs.
Conclusions:
- CT26 colon carcinoma cells inhibit DC maturation through the induction of STAT3 phosphorylation.
- Tumor-induced STAT3 activation in DCs contributes to immune evasion in colon cancer.
- Targeting tumor-induced p-STAT3 in DCs represents a promising strategy for colon cancer immunotherapy.
